People living with amyotrophic lateral sclerosis (ALS) in the U.S. generally prefer care models where they can see multiple healthcare providers during the same visit, rather than only regularly seeing a neurologist who refers them to other doctors as needed, according to a new study. The findings have important…
ALS patients, caregivers prefer team-based care model, new survey finds
Up to six people with advanced amyotrophic lateral sclerosis (ALS) will be treated with Trethera’s experimental therapy TRE-515 under a collaboration with Massachusetts General Hospital (MGH). The patients will receive the oral treatment through a U.S. Food and Drug Administration (FDA) expanded access program (EAP), which allows people…
When my husband Todd’s new power wheelchair was delivered, he tried a device that allowed him to control it with his eyes. It included software running on a tablet computer and an eye-tracking system mounted to the front of the chair. He found the system frustrating because he was…
A pivotal Phase 3 clinical trial testing pridopidine, an experimental oral therapy being developed by Prilenia Therapeutics and Ferrer, in people with early, rapidly progressive amyotrophic lateral sclerosis (ALS) has enrolled its first participant. PREVAiLS (NCT07322003), which was cleared late last year by the…
Brooke Eby, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2022 at age 33, has been named the ALS Network’s 2026 Dean and Kathleen Rasmussen Advocate of the Year for turning her personal experience as an ALS patient into a platform for advocacy, community building, and awareness. The…
Tanabe Pharma Canada has announced the publication of a new book featuring personal letters from people living with amyotrophic lateral sclerosis (ALS) and their families, with contributions from advocates, healthcare professionals, and researchers. The book, “Letters to ALS: Our Journeys to Hope,” is available free of charge to…
Insitro and Bristol Myers Squibb have expanded their ongoing collaboration to develop new treatments for amyotrophic lateral sclerosis (ALS), adding two newly identified disease targets to their ongoing research effort. The two drug companies have been working together since 2020 to uncover biological changes driving ALS…
The first patient has been dosed in a small clinical trial in Australia that’s testing CTx1000, Celosia Therapeutics’ experimental gene therapy, in people with amyotrophic lateral sclerosis (ALS). The one-time treatment is designed to reduce toxic buildups of the TDP-43 protein, which are believed to contribute to nerve cell…
My husband, Todd, and I work on New York Times puzzles while we eat breakfast. I sit next to him and feed him bites of his breakfast while I eat, too. One puzzle we work on is the Spelling Bee, where we earn points by forming words from seven different…
ACI-19626, an experimental imaging agent developed by AC Immune, may safely detect abnormal clumps of the protein TDP-43 in the brain, a hallmark of amyotrophic lateral sclerosis (ALS) and other neurological conditions. That’s according to early data from a Phase 1 clinical trial (NCT06891716) evaluating the safety and…
Recent Posts
- We must each find our own way as we learn to live with ALS
- Exposure to pesticide HCB may raise risk of ALS, new study finds
- Swallowing problems affect 1 in 3 hospitalized ALS patients: Study
- Scientists identify blood markers that may predict ALS progression
- ALS caregivers across Canada can now access free professional counseling